Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Conditions
Interventions
Placebo
Lumacaftor Plus Ivacaftor Combination
+1 more
Locations
82
United States
Oakland, California, United States
Sacramento, California, United States
Aurora, Colorado, United States
Hartford, Connecticut, United States
New Haven, Connecticut, United States
Jacksonville, Florida, United States
Start Date
April 1, 2013
Primary Completion Date
April 1, 2014
Completion Date
April 1, 2014
Last Updated
September 27, 2016
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions